Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

19941,012 citationsJournal Article

Authors

Steven A. Rosenberg

John R. Yannelli · National Cancer Institute

James Chih‐Hsin Yang · National Cancer Institute

Suzanne L. Topalian · National Cancer Institute

Douglas J. Schwartzentruber · National Cancer Institute

Jeffrey S. Weber · National Cancer Institute

David Parkinson · National Cancer Institute

Abstract

Treatment with TILs and IL-2 with or without cyclophosphamide can result in objective responses in about one third of patients with metastatic melanoma. The side effects of treatment are transient in most patients, and this treatment can be safely administered. These results illustrate the potential value of immune lymphocytes for the treatment of patients with melanoma.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Toxin Mechanisms and Immunotoxins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 86, Issue 15, pp. 1159-1166

DOI: 10.1093/jnci/86.15.1159

Field-Weighted Citation Impact: 9.60